Diabetologia

, Volume 48, Issue 5, pp 878–885

Molecular genetics and phenotypic characteristics of MODY caused by hepatocyte nuclear factor 4α mutations in a large European collection

  • E. R. Pearson
  • S. Pruhova
  • C. J. Tack
  • A. Johansen
  • H. A. J. Castleden
  • P. J. Lumb
  • A. S. Wierzbicki
  • P. M. Clark
  • J. Lebl
  • O. Pedersen
  • S. Ellard
  • T. Hansen
  • A. T. Hattersley
Article

DOI: 10.1007/s00125-005-1738-y

Cite this article as:
Pearson, E.R., Pruhova, S., Tack, C.J. et al. Diabetologia (2005) 48: 878. doi:10.1007/s00125-005-1738-y

Abstract

Aims/hypothesis

Heterozygous mutations in the gene of the transcription factor hepatocyte nuclear factor 4α (HNF-4α) are considered a rare cause of MODY with only 14 mutations reported to date. The description of the phenotype is limited to single families. We investigated the genetics and phenotype of HNF-4α mutations in a large European Caucasian collection.

Methods

HNF-4α was sequenced in 48 MODY probands, selected for a phenotype of HNF-1α MODY but negative for HNF-1α mutations. Clinical characteristics and biochemistry were compared between 54 HNF-4α mutation carriers and 32 familial controls from ten newly detected or previously described families.

Results

Mutations in HNF-4α were found in 14/48 (29%) probands negative for HNF-1α mutations. The mutations found included seven novel mutations: S34X, D206Y, E276D, L332P, I314F, L332insCTG and IVS5nt+1G>A. I314F is the first reported de novo HNF-4α mutation. The average age of diagnosis was 22.9 years with frequent clinical evidence of sensitivity to sulphonylureas. Beta cell function, but not insulin sensitivity, was reduced in diabetic mutation carriers compared to control subjects (homeostasis model assessment of beta cell function 29% p<0.001 vs controls). HNF-4α mutations were associated with lower apolipoprotein A2 (p=0.001), A1 (p=0.04) and total HDL-cholesterol (p=0.02) than in control subjects. However, in contrast to some previous reports, levels of triglycerides and apolipoprotein C3 were normal.

Conclusions/interpretation

HNF-4α mutations are common when no HNF-1α mutation is found in strictly defined MODY families. The HNF-4α clinical phenotype and beta cell dysfunction are similar to HNF-1α MODY and are associated with reduced apolipoprotein A2 levels. We suggest that sequencing of HNF-4α should be performed in patients with clinical characteristics of HNF-1α MODY in whom mutations in HNF-1α are not found.

Keywords

Apolipoprotein A1Apolipoprotein A2DiabetesHepatocyte nuclear factor 4 αHNF-4αMODYP2 promoterTranscription factors

Abbreviations

Apo

Apolipoprotein

HNF-4α

Hepatocyte nuclear factor 4α

HOMA

Homeostasis model assessment

Lp

Lipoprotein

Introduction

The orphan nuclear receptor hepatocyte nuclear factor 4α (HNF-4α) plays a fundamental role in the complex transcription factor network that regulates liver and pancreatic islet development and function [1]. In mice, homozygous knockout of HNF-4α (the gene encoding HNF-4α) is lethal at an early embryonic stage; however, the heterozygous knockout has no phenotype. In humans, heterozygous mutations in HNF-4α cause a phenotype that is predominantly characterised by MODY [2].

Despite the description of HNF-4α mutations as a cause of MODY in 1996 [2], only 11 coding region mutations and one splice site mutation (in 13 families) have been published in MODY families: F75fsdelT [3]; K99fsdelAA [4]; G115S [5]; V121I [6]; R125W [7]; R127W [8, 9]; R154X [10]; V199I [11]; R244Q [7]; Q268X [2]; E276Q [12]; IVS5-2delA [13]. More recently, a pancreatic specific P2 promoter 46 kb upstream of the HNF-4α transcription start site has been identified [14]. Two mutations in this P2 promoter have been described: −181G>A [15] in an HNF-1α binding site; and −146T>C [14] in an IPF-1 (PDX-1) binding site. Additionally, a balanced translocation with a breakpoint between the P2 promoter and the HNF-4α gene has also been shown to cause MODY [16]. The small number of mutations in HNF-4α is in contrast to more than 120 in HNF-1α [17] and 195 mutations (281 families) in glucokinase [18]. HNF-4α mutations are reported to have a prevalence of between 2 and 5% of all MODY cases [5, 7, 19]. Diagnostic genetic services for diabetes frequently only offer HNF-1α and glucokinase testing; HNF-4α is rarely tested.

In the pancreas HNF-1α activates transcription of HNF-4α, via the P2 promoter, which in turn activates HNF-1α transcription. It has been proposed that this feed-forward loop acts as a bistable switch [20], such that haploinsufficiency of either HNF-1α or HNF-4α causes the switch to turn off. This model predicts a similar pancreatic phenotype for HNF-1α and HNF-4α mutations. In the liver the picture is not as clear, with some studies reporting primarily P1 transcripts [15] and other studies reporting both P1- and P2-derived transcripts [1, 14]. The P1 promoter does not contain an HNF-1α binding site so the feed-forward loop seen in the pancreas plays a lesser or no role in the liver. Thus a different ‘hepatic’ phenotype (e.g. lipid metabolism) might be predicted to result from HNF-1α and HNF-4α mutations.

To date, published phenotypic data on HNF-4α mutation carriers is of single families—notably the extensively studied ‘RW’ family in whom HNF-4α mutations were first described [2]. In the RW family, carrying the Q268X mutation, the primary defect was established as decreased beta cell insulin secretion with normal insulin sensitivity [21, 22], decreased alpha cell [23] and decreased delta cell [24] function. Similarly, a Swedish family (DS) has been well characterised with normal insulin-stimulated glucose uptake in a euglycaemic clamp, and decreased beta cell response to glucagon, intravenous glucose, oral glucose and a test meal [4]. In these two families HNF-4α mutation carriers have low circulating triglycerides and apolipoprotein (Apo) concentrations [4, 25]. Consistent with this, a liver-specific HNF-4α knockout mouse has reduced fasting serum levels of total cholesterol, HDL, triglycerides and Apos, suggesting a role of hepatic HNF-4α in lipid homeostasis [26]. However, three other families with HNF-4α mutation carriers had normal fasting levels of triglycerides [3, 10, 11] and lipoproteins [10, 11], although these studies were smaller.

Rare mutations in HNF-4α have been found in type 2 diabetes [27, 28], but recently a more prevalent role in the susceptibility to type 2 diabetes has been described. In two studies, a haplotype spanning the HNF-4α P2 promoter was associated with type 2 diabetes with odds ratios of 1.33 [29] and 1.45 [30]. Thus, not only do HNF-4α mutations cause MODY, but common variation within the regulatory region of this gene is associated with a genetic predisposition to type 2 diabetes. Therefore, understanding the monogenic phenotype may provide insight into the role of the HNF-4α gene in the more complex type 2 diabetes.

The aims of our study were to define the molecular genetics of HNF-4α in probands selected on the basis of clinical criteria and who did not have mutations in the HNF-1α gene. We also aimed to assess pancreatic function and lipid metabolism in the largest reported collection of families with MODY caused by HNF-4α mutations.

Subjects and methods

Molecular genetics

Clinical referrals for MODY genetic testing to the UK Exeter laboratory between 1997 and 2004 were selected on the basis of the following clinical criteria:
  1. 1)

    at least one family member diagnosed with type 2 diabetes by WHO criteria before 25 years of age

     
  2. 2)

    at least a two-generation family history of diabetes

     
  3. 3)

    absence of features suggestive of young-onset type 2 diabetes, namely marked insulin resistance and obesity (BMI >30 kg/m2)

     
  4. 4)
    presence of one or more of the following clinical and biochemical phenotypes suggestive of HNF-1α rather than glucokinase MODY [31, 32]:
    1. i)

      progressive deterioration in glucose tolerance leading to increasing hyperglycaemia and/or treatment requirements

       
    2. ii)

      evidence of marked hyperglycaemia as shown by an HbA1c >4 SD above normal

       
    3. iii)

      fasting glucose documented below 5.5 mmol/l, in a subject who subsequently developed diabetes

       
    4. iv)

      OGTT showing an increment in glucose concentration between fasting and 120-min values of >4.5 mmol/l

       
     

Using these criteria, 261 subjects were selected for HNF-1α testing. Of these, 117 were found to have HNF-1α mutations. HNF-4α was sequenced in 48 HNF-1α-negative probands from the remaining 144 subjects. All patients were Caucasian.

Genomic DNA was amplified using published primers for the P2 promoter [14], P1 promoter, exons 1–10 and splice sites [2]. PCR products were purified and sequenced using BigDye Terminator chemistry (Applied Biosystems, Warrington, UK). Reactions were analysed on an ABI Prism 377 or 3100 DNA Sequencer (Applied Biosystems) and sequences compared using Sequence Navigator software.

Subjects for clinical studies

Fifty-four HNF-4α mutation carriers and 32 non-mutation carriers (control subjects) were recruited from ten European Caucasian families: eight families had mutations within the coding region of HNF-4α; six British ([9, 12], and four families from this series), one Danish [3] and one Czech [7]. Two families had mutations within the pancreatic specific P2 promoter: one Czech [15] and one Dutch [14]. This study was approved by the North and East Devon Local Research Ethics committee, and all participants gave written informed consent.

Methods for clinical studies

Following an overnight fast, blood was collected and centrifuged within 1 h at 3000 rpm for 10 min. Serum and plasma were stored at −70°C. All biochemistry was performed in the same UK laboratories, samples having been transported frozen on dry ice. Patients treated with lipid-lowering agents (n=4) were excluded from the analysis of biochemistry data. Children aged less than 16 years and pregnant women were excluded from all biochemical analysis. Plasma glucose and insulin levels were measured. For insulin analysis, isophane insulin was omitted for 24 h, soluble insulin was omitted for 12 h and oral hypoglycaemic agents were omitted for 48 h prior to blood sampling. Insulin was measured by an immunoenzymometric assay (Insulin EASIA; Biosource, Nivelles, Belgium) calibrated against the International Reference Preparation 66/304 with no detectable cross-reactivity with intact proinsulin and 32–33 split proinsulin and reported as pmol/l. Serum lipids and a liver profile including transaminases were measured by standard automated methods. LDL-cholesterol was calculated by the Friedewald equation, as all triglyceride concentrations were lower than 4.5 mmol/l (400 mg/dl). Apolipoproteins A1, A2, B100, C2, C3 and lipoprotein (Lp)-a were measured by turbidimetric methods on a Cobas Fara 2 analyser (Roche, Welwyn, UK) using Dako polyclonal antisera. High-sensitivity CRP was by nephelometric technique on a BN2 analyser (Dade Behring, Milton Keynes, UK).

Calculation of insulin sensitivity and beta cell function

Insulin sensitivity and beta cell function were determined using the homeostasis model assessment (HOMA) computer model [33, 34].

Statistical analysis

Where data showed a skewed distribution, they were log-transformed to normality. HNF-4α coding and P2 mutation groups were analysed together and compared with familial controls. Baseline characteristics and measures of beta cell function and insulin sensitivity were compared using independent samples t-test and chi square test. Comparison of lipid and liver enzyme biochemistry was by univariate analysis using HNF-4α genotype and family number as fixed factors. An effect of genotype on a biochemical marker was only taken to be significant if the HNF-4α genotype p value was less than 0.05 with no significant interaction between factors.

Results

Molecular genetics

HNF-4α mutations were found in 14/48 (29%) of probands who were negative for HNF-1α mutations. Of these, three pedigrees have been previously described: E276Q [12], R127W [9], P2−146T>C [14]; three further probands were found to have the R127W mutation, and eight probands had seven novel mutations: S34X, D206Y, E276D, I314F, L332P (two families), L332insCTG and IVS5nt+1G>A. The pedigrees showing age of diagnosis and treatment for these novel mutations and unpublished R127W mutations are shown in Fig. 1. Microsatellite analysis [35] confirmed that I314F mutation is a de novo HNF-4α gene mutation.
Fig. 1

Pedigrees of families with novel and unpublished HNF-4α mutations. Filled symbols represent diabetes, shaded symbols represent gestational diabetes, open symbols represent no diabetes. Genotype NN, no mutation; NM, heterozygous HNF-4α mutation; OHA, oral hypoglycaemic drugs. The age is the age diagnosed with diabetes in individuals with diabetes, or current age in subjects who do not have diabetes. The treatment is diet, OHA, or insulin

Clinical and biochemical phenotypes

The clinical characteristics of the 54 HNF-4α mutation carriers and 32 familial control subjects for the phenotype study are shown in Table 1. Both groups were well matched for age and BMI. The HNF-4α mutation carriers consisted of 42 diabetic subjects diagnosed at a mean of 22.9 years (range 5–48) and 12 subjects who did not have diabetes (no treatment and fasting glucose <7 mmol/l). The non-diabetic mutation carriers’ mean age was 22.6 (range 9–38) and they had a similar BMI and WHR to the diabetic subjects, despite being younger. Accounting for family of origin had no effect on these results. The non-diabetic mutation carriers were from six families and age of onset had no correlation with site or type of mutation within the gene (data not shown). Twenty two patients were known to have received sulphonylureas and ten (45%) showed clinical features suggestive of a good hypoglycaemic response to this treatment: six are being managed with low doses of sulphonylureas (requiring 12.5% or less of the maximum licensed dose); two patients are still being treated with sulphonylureas after 33 and 34 years of treatment; and two patients were treated with sulphonylureas for 28 and 37 years before requiring insulin.
Table 1

Baseline characteristics of patients with HNF-4α mutations and matched familial controls

 

HNF-4α

Control

p value

Number

54

32

 

Mutations

S34X, F75fsdelT, R127W*3, D206C, E276Q, I314F, −181G>A, −146T>C

  

Age (range) years

38.9 (9–78)

35.3 (11–63)

0.30

Sex male/female

19/35

17/15

0.18

BMI (SD) kg/m2

25.1(3.7)

25.0 (3.7)

0.92

  Male/female

25.3/25.0

25.9/24.1

 

WHR (SD)

0.87 (0.13)

0.88 (0.10)

0.76

  Male/female

0.92/0.85

0.93/0.82

 

Diabetes

 Number

42

  

 Sex male/female

17/25

  

 Age (range) years

43.9 (14–78)

  

 Age diagnosed (range)

22.8 (5–48)

  

 BMI (SD) kg/m2

25.7 (3.5)

  

 WHR (SD)

0.89 (0.14)

  

 Treatment none/OHA/insulin (in %)

10/50/40

  

No diabetes

 Number

12

  

 Sex male/female

2/10

  

 Age (range) years

22.6 (9–38)

  

 BMI (SD) kg/m2

23.2 (4.16)

  

 WHR (SD)

0.81 (0.07)

  

OHA oral hypoglycaemic agent

The fasting plasma insulin, glucose and HOMA B (beta cell function) and S (insulin sensitivity) indices are shown in Table 2. The diabetic group had decreased beta cell function but normal insulin sensitivity compared to control subjects. The non-diabetic group of HNF-4α mutation carriers had similar beta cell function and insulin sensitivity compared with control subjects. The levels of fasting serum lipids in the HNF-4α mutation carriers and control subjects are shown in Table 3. HDL-cholesterol (p=0.023), ApoA1 (p=0.042) and ApoA2 (p=0.001) were reduced in the mutation carriers (HNF-4α genotype) independently of variation between the families. This suggests that a specific reduction in the Lp A1–A2 sub-fraction of HDL occurs in patients with HNF-4α mutations. Interestingly, there was no significant effect of genotype on fasting serum levels of triglycerides although there was a highly significant interaction (p<0.001) between the genotype and family factors, meaning that the effect of the HNF-4α genotype on triglycerides varies between families. LDL-cholesterol (p=0.01) and ApoB100 (p=0.02) were increased in mutation carriers consistent with the observed decrease in reverse cholesterol transport associated Lps, although again there was a significant interaction between the genotype and family factors making interpretation of these results difficult. No differences were found in fasting serum concentrations of triglycerides, ApoC2, ApoC3 or lipoprotein(a).
Table 2

Fasting serum insulin levels and HOMA-B and -S indices of patients with HNF-4α mutations divided by presence or absence of diabetes and familial controls

 

HNF-4α

Control

p value

Diabetes

Non-diabetes

Diabetes vs control

Non-diabetes vs control

Number

29

5

29

  

Glucose mmol/l

10.0 (4.4)

4.8 (0.6)

5.0 (0.7)

<0.001

0.65

Insulin pmol/l

74 (49–111)

79 (47–132)

93 (56–154)

0.06

0.885

HOMA B % of control

29 (15–56)

97 (68–139)

100 (67–160)

<0.001

0.49

HOMA S % of control

100 (60–168)

118 (71–196)

100 (62–162)

0.975

0.52

Data presented as mean (SD) or geometric mean (SD range)

Table 3

Biochemical profiles of patients with HNF-4α mutations and matched familial controls

 

HNF-4α

Control

ANOVA p value

Family

HNF-4α genotype

Number

42

29

  

Age years

40.6 (15.1)

37.5 (12.6)

0.89

0.31

Sex male/female

28/16

14/15

  

BMI kg/m2

25.3 (3.6)

25.4 (3.5)

0.018

0.79

Glucose, mmol/la

9.1 (4.3)

5.0 (0.61)

0.13

<0.001

Total cholesterol, mmol/l

5.5 (1.0)

5.4 (1.1)

0.07

0.23

HDL-cholesterol, mmol/la

1.5 (0.46)

1.8 (0.42)

0.024

0.023

LDL-cholesterol, mmol/l

3.4 (2.5–4.5)

2.9 (2.1–3.9)

0.006

0.011

Triglycerides, mmol/l

1.13 (0.66–1.94)

1.12 (0.72–1.72)

0.001

0.09

ApoA1, g/la

1.48 (0.29)

1.65 (0.28)

0.016

0.042

ApoA2, g/la

0.33 (0.07)

0.40 (0.08)

0.006

0.001

ApoB, g/la

0.95 (0.21)

0.86 (0.27)

0.012

0.019

ApoC2, mg/dl

2.93 (1.82–4.72)

1.61 (1.07–2.4)

0.162

0.55

ApoC3, mg/dl

13.3 (4.36)

14.7 (3.3)

0.001

0.85

Lp(a), g/l

0.095 (0.03–0.28)

0.095 (0.04–0.25)

0.032

0.85

hsCRP, mg/l

1.24 (0.44–3.46)

0.93 (0.42–2.08)

0.026

0.245

ALT, IU/l

16 (9–27)

21 (13–34)

<0.001

0.53

ALP, IU/l

63 (40–98)

67 (43–103)

0.13

0.38

Bilirubin, μmol/l

12 (7–21)

12 (8–17)

0.09

0.89

Albumin, g/l

45 (3)

47 (3)

0.16

0.25

Data are presented as mean (SD) or geometric mean (SD range)

aResults where the HNF-4α genotype is significant at p<0.05 with no significant interaction family*genotype. ALP alkaline phosphatase, ALT alanine aminotransferase

Discussion

We have described 11 previously unreported families with mutations in HNF-4α, including seven novel mutations and the first description of a spontaneous mutation in this gene. We highlight that sequencing HNF-4α is important in families with clinical characteristics suggestive of HNF-1α MODY who do not have an HNF-1α mutation. We have also characterised the diabetes phenotype and lipid phenotype in a large European collection of patients, and confirm reports from individual families of decreased beta cell function, normal insulin sensitivity and reduced ApoA2 (HDL LpA1–A2) in HNF-4α mutation carriers.

The HNF-4α mutations occurring in previously unreported families are S34X, R127W (three families), D206Y, E276D, L332P (two families), I314F, L332insCTG, and IVS5nt+1G>A. Only R127W has been reported before; this was seen in one UK and one Japanese family and is now the most common mutation described in HNF4-α. The position of these mutations and previously published mutations are shown in Fig. 2. The nonsense mutation S34X will result in a truncated protein with marked loss of HNF-4α function, as it lacks a transactivating domain. The intronic mutation IVS5nt+1G>A is at a splice donor site and likely to be pathogenic. The E276D missense mutation occurs at the same amino acid as the previously reported E276Q. The other missense mutations (D206Y, L332P and I314F) and the in-frame insertion (L332insCTG) are also likely to be pathogenic as there is conservation of the amino acid residues involved between human, rat, mouse and xenopus; and they co-segregate with diabetes in families. It is impossible to completely rule out that these are rare polymorphisms without performing functional studies, especially as some families are small and so co-segregation could occur by chance. Microsatellite analysis confirmed a de novo mutation I314F, and this is the first report of a spontaneous mutation in HNF-4α. Interestingly, two mutations in three families occurred within a polyCTG tract encoding five leucine residues (codons 328–332) and which is a likely binding site for co-regulators, including SHP which inhibits transcriptional activity of HNF-4α [36, 37].
Fig. 2

Diagram to show the location of the 20 reported HNF-4α gene mutations in 26 MODY families (recurrent mutations with number of families in brackets). The 13 exons of the HNF-4α gene (including the alternatively spliced exons 1a, 1b, 1c and 1d) and two promoters (P2 and P1) are shown. The P2 promoter is located 46 kb upstream from the P1 promoter and is the predominant isoform in the pancreas. A balanced translocation with a breakpoint between the P2 promoter and exon 2 has also been reported to cause MODY [16]. P1 is the predominant promoter in the liver. Novel mutations reported in this study are shown in italics

We found HNF-4α mutations in 29% of our MODY patients selected on the basis of clinical characteristics and not having an HNF-1α mutation. This report increases the number of MODY families with HNF-4α mutations from 16 to 27. The low number of HNF-4α mutations reported to date may reflect the fact that the gene is often not sequenced or that subjects with an inappropriate phenotype are tested. As our data are based on a selected group of patients, it does not represent a prevalence figure but can be used to guide protocols for clinical testing. Clinical selection can considerably reduce the amount of genotyping, especially as the two most common types of MODY, i.e. those due to HNF-1α and glucokinase mutations, have markedly different phenotypes [32, 38]. We found 116 (44%) HNF-1α mutations in 261 subjects referred to the UK Exeter laboratory with clinical characteristics supportive of non-glucokinase or HNF-1a MODY. Of those without an HNF-1α mutation, 14 of 48 (29%) tested were found to have HNF-4α mutations. This supports a three-step approach: selection on clinical criteria; sequencing for HNF-1α mutations; then, if this is negative, sequencing for HNF-4α mutations.

The mean age of onset of diabetes (23 vs 20 years), the percentage requiring oral agents (50 vs 43%) and percentage requiring insulin (40 vs 31%) were similar in this HNF-4α series and in a series of HNF-1α mutation carriers from 59 MODY families [19]. HNF-1α mutation carriers are sensitive to the hypoglycaemic effects of sulphonylurea drugs [39, 40]. This study was not a formal study of sulphonylurea sensitivity, but the low doses used, and long duration of treatment would be consistent with sulphonylurea sensitivity in MODY due to HNF-4α mutations. This finding of sensitivity to sulphonylureas was also apparent in a prospective study of 12 HNF-4α patients from the ‘RW family’, where insulin secretion in response to oral glucose has been markedly augmented by sulphonylureas for up to 33 years [41]. HOMA analysis suggested a marked beta cell defect in the diabetic subjects, but no reduction in insulin sensitivity. Thus, the diabetes phenotypes due to HNF-1α mutations and HNF-4α mutations are clinically similar. This is consistent with the prediction of Ferrer’s bistable switch hypothesis [20] and supports the proposed sequential approach of sequencing HNF-4α after HNF-1α.

The clinical and biochemical study is on the largest collection of HNF-4α families collected to date. Previous studies have been on individual families and it is therefore not possible to say what is a general feature of HNF-4α mutations and what is a mutation-specific effect. The strength of this study is that a large sample size, with numerous mutations, allows for applicability of results to the whole HNF-4α population. However, this study is limited in that when collecting numerous families, there is large inter-familial variation in a number of the biochemistry results, despite their being analysed in a single laboratory as a single batch, which means that small genotype-specific effects could not be detected reliably.

In the pancreas, most studies report that the HNF-4α transcripts present are derived exclusively from the P2 promoter [1, 14, 15]. In the liver the picture is not as clear, with some studies reporting primarily P1 transcripts [15]; or transcripts from both the P1 and P2 promoter [1, 14]. In the former case, the MODY patients with a P2 promoter mutation would be predicted to have a normal hepatic phenotype, i.e. normal circulating levels of Apos and triglycerides; in the latter case, an intermediate phenotype might be predicted. The large variation between families meant that we were unable to compare the two families with HNF-4α P2 promoter mutations with those families with coding mutations. However, if the mutation carriers (n=7) are compared with their familial controls (n=4) in the largest P2 family (−146T>C [14]), then serum ApoA2 levels were similar (0.41 vs 0.38 g/l, p=0.54), as were all the other lipid variables. It is not possible to say if this reflects the small sample size or a true lack of P2 mutations to affect Apo synthesis.

HNF-4α regulates Apo transcription by the liver. In an elegant study, Shih et al. [25] show firstly that loss of HNF-4α function in embryoid body cells results in decreased expression of ApoA1, ApoA2, ApoB and ApoC3. Secondly they report that diabetic and non-diabetic subjects from the RW family with HNF-4α mutations have low serum levels of triglycerides, ApoC3, ApoA2 and lipoprotein(a). The 18 subjects with the Q268X mutation are highly homogeneous, with a mean age of onset (+SD) of diabetes of 14±1 years while the HbA1c of the diabetic group was only 6.4±0.5%. In a separate study six carriers of the K99fsdelAA mutation [4] also had low serum levels of ApoC3 and triglycerides, but ApoA2 levels were normal. In the mouse, a liver-specific knockout had low serum HDL-C, LDL-C and triglycerides; and reduced expression of ApoA2, ApoA4, ApoC2 and ApoC3 in the liver [26]. By contrast, six subjects with the R154X mutation [10] and three subjects with a R127W mutation in HNF-4α had normal serum triglycerides and Apos and elevated Lp(a); and three subjects with the V199I [11] mutation had normal serum triglycerides and Apos. The findings in the human studies are conflicting, but the most consistent finding from these studies and the mouse and cell models is that loss of function of HNF-4α is associated, at least in some families, with reduced circulating concentrations of ApoA2, ApoC3 and triglycerides.

In this study we show a highly significant reduction in serum ApoA2 in HNF-4α mutation carriers. This is in keeping with the literature and suggests that this is a consistent finding across different mutations. Ours is the only study on human subjects to show a lower serum HDL-cholesterol in HNF-4α mutation carriers than in control subjects. This may reflect the unusually high serum HDL-cholesterol (1.8 mmol/l) in the control group, although low serum HDL-cholesterol has been described in the knockout mouse [26]. Serum ApoA2 is a major component of HDL and these are correlated in our data (r=0.48, p<0.001); it is likely that the low total serum HDL-cholesterol is secondary to a low transcription of ApoA2 and a specific deficiency in the serum LpA1–A2 subfraction of HDL. It is interesting that two published HNF-4α mutations are associated with low levels of serum triglycerides and ApoC3, and three are not, indicating variable effects of HNF-4α on triglyceride-rich remnant lipoprotein metabolism. No significant correlation of genotype with serum triglyceride levels was seen in this study. This may reflect the heterogeneity in our group, and the fact that the diabetes control was not as tight as in the study by Shih et al. [25]. However, the highly significant interaction between the family (hence mutation) factor and the genotype might suggest a genotype/phenotype correlation between type or site of mutation and serum triglyceride and ApoC3 levels. The normal serum triglyceride levels in the HNF-4α mutation carriers in this study mean that, clinically, serum triglyceride levels are not a useful phenotypic marker for HNF-4α mutations.

Two studies in a Finnish [29] and Ashkenazi–Jewish [30] population show an association between a haplotype spanning the HNF-4α P2 promoter and type 2 diabetes. The Finnish study looked at quantitative traits in unaffected offspring, and showed that the risk allele at SNP rs2144908 was associated with decreased beta cell function, normal insulin sensitivity and normal serum lipid concentrations. Serum HDL-cholesterol was also normal in this group, although it was lower in the spouse controls who were homozygous for the risk allele. These results are similar to those seen in our study of monogenic HNF-4α mutations. Thus studying a monogenic phenotype may provide insight into a polygenic disease. It would be interesting to study circulating ApoA2 levels and HDL-lipoprotein subfraction profiles according to SNP rs2144908 genotype, as studies in monogenic disease would predict reduced levels in those carrying the risk allele.

In conclusion, we have shown that HNF-4α mutations are common when HNF-1α sequencing is negative in strictly defined MODY families and report eleven unpublished (including seven novel) mutations. The HNF-4α MODY clinical phenotype and beta cell dysfunction are similar to HNF-1α MODY. A consistent deficiency in the fasting serum ApoA2 level and consequently HDL LpA1–A2 level was seen in our large collection of HNF-4α families and probably reflects a direct effect of reduced HNF-4α on ApoA2 synthesis in the liver. We suggest that in patients with clinical characteristics of HNF-1α MODY, HNF-4α should be sequenced, if a mutation is not found in the HNF-1α gene.

Acknowledgements

This study was funded by the Wellcome Trust. E. R. Pearson holds a Wellcome Trust clinical training fellowship, and A. T. Hattersley a Wellcome Trust career leave fellowship. C. J. Tack is a recipient of a clinical research fellowship of the Dutch Diabetes Foundation. The collection of Danish samples was supported by grants from the Danish Diabetes Association and The Danish Medical Research Council and the collection of Czech samples was funded by grant IGA Mzd CR NB 7420-3. The molecular genetic analysis was performed by Julie Evans, Kate Thomson, Kevin Colclough and Simon Mitchell. We would like to acknowledge all the patients and their referring clinicians.

Copyright information

© Springer-Verlag 2005

Authors and Affiliations

  • E. R. Pearson
    • 1
  • S. Pruhova
    • 2
  • C. J. Tack
    • 3
  • A. Johansen
    • 4
  • H. A. J. Castleden
    • 1
  • P. J. Lumb
    • 5
  • A. S. Wierzbicki
    • 5
  • P. M. Clark
    • 6
  • J. Lebl
    • 2
  • O. Pedersen
    • 4
  • S. Ellard
    • 1
  • T. Hansen
    • 4
  • A. T. Hattersley
    • 1
  1. 1.Diabetes and Vascular Medicine, Institute of Biomedical and Clinical SciencePeninsula Medical SchoolExeterUK
  2. 2.Department of Paediatrics, 3rd Faculty of MedicineCharles UniversityPragueCzech Republic
  3. 3.Division of General Internal Medicine, 541University Medical Centre NijmegenNijmegenThe Netherlands
  4. 4.Steno Diabetes Centre and Hagedorn Research InstituteCopenhagenDenmark
  5. 5.Department of Chemical PathologySt Thomas’ HospitalLondonUK
  6. 6.Regional Endocrine LaboratoriesUniversity Hospital BirminghamBirminghamUK